Apathy in Parkinson's disease: Clinical features, neural substrates, diagnosis, and treatment

The Lancet Neurology

Volumn 14, Issue 5, 2015, Pages 518-531

  Pagonabarraga, Javier ^a,b,c   Kulisevsky, Jaime ^a,b,c,d   Strafella, Antonio P ^e,f   Krack, Paul ^g,h  

^a HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^b UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^c Centro Investigación Biomédica en Red Enfermedades Neurodegenerativas   (Spain)

^d UNIVERSITAT OBERTA DE CATALUNYA   (Spain)

^e TORONTO WESTERN HOSPITAL   (Canada)

^f UNIVERSITY OF TORONTO   (Canada)

^g GRENOBLE UNIVERSITY HOSPITAL   (France)

^h GRENOBLE INSTITUT DES NEUROSCIENCES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AMITRIPTYLINE; CITALOPRAM; LEVODOPA; METHYLPHENIDATE; MIRTAZAPINE; PRAMIPEXOLE; RACLOPRIDE C 11; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR;

APATHY; BRAIN DEPTH STIMULATION; CAREGIVER; CLINICAL FEATURE; COGNITIVE DEFECT; DEGENERATIVE DISEASE; DEPRESSION; HUMAN; IMPULSE CONTROL DISORDER; MENTAL PERFORMANCE; PARKINSON DISEASE; POSITRON EMISSION TOMOGRAPHY; PREFRONTAL CORTEX; PREVALENCE; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; CASE REPORT; MALE; MIDDLE AGED; PATHOPHYSIOLOGY;

APATHY; HUMANS; MALE; MIDDLE AGED; PARKINSON DISEASE;

EID: 84928039067     PISSN: 14744422     EISSN: 14744465     Source Type: Journal    
DOI: 10.1016/S1474-4422(15)00019-8     Document Type: Review

References (157)

1. Marin RS Apathy: a neuropsychiatric syndrome. J Neuropsychiatry Clin Neurosci 1991, 3:243-254.
2. Levy R, Dubois B Apathy and the functional anatomy of the prefrontal cortex-basal ganglia circuits. Cereb Cortex 2006, 16:916-928.
3. Marin RS Apathy: concept, syndrome, neural mechanisms, and treatment. Semin Clin Neuropsychiatry 1996, 1:304-314.
4. Starkstein SE Apathy in Parkinson's disease: diagnostic and etiological dilemmas. Mov Disord 2012, 27:174-178.
5. Neisser U Cognitive Psychology 1967, Prentice Hall, Englewood Cliffs, NJ.
6. Kirsch-Darrow L, Marsiske M, Okun MS, Bauer R, Bowers D Apathy and depression: separate factors in Parkinson's disease. J Int Neuropsychol Soc 2011, 17:1058-1066.
7. Zahodne LB, Marsiske M, Okun MS, Bowers D Components of depression in Parkinson disease. J Geriatr Psychiatry Neurol 2012, 25:131-137.
8. Dujardin K, Langlois C, Plomhause L, et al. Apathy in untreated early-stage Parkinson disease: relationship with other non-motor symptoms. Mov Disord 2014, 29:1796-1801.
9. Funkiewiez A, Ardouin C, Caputo E, et al. Long term effects of bilateral subthalamic nucleus stimulation on cognitive function, mood, and behaviour in Parkinson's disease. J Neurol Neurosurg Psychiatry 2004, 75:834-839.
10. Martínez-Horta S, Pagonabarraga J, Fernández de Bobadilla R, García-Sanchez C, Kulisevsky J Apathy in Parkinson's disease: more than just executive dysfunction. J Int Neuropsychol Soc 2013, 19:571-582.
11. Brown RG, Pluck G Negative symptoms: the 'pathology' of motivation and goal-directed behaviour. Trends Neurosci 2000, 23:412-417.
12. Kuhl J, Atkinson JW Motivation, thought, and action 1986, Praeger Publishers, New York.
13. McCutcheon JE, Ebner SR, Loriaux AL, Roitman MF Encoding of aversion by dopamine and the nucleus accumbens. Front Neurosci 2012, 6:137.
14. Mellers BA, Schwartz A, Cooke AD Judgment and decision making. Annu Rev Psychol 1998, 49:447-477.
15. Mogenson GJ, Jones DL, Yim CY From motivation to action: functional interface between the limbic system and the motor system. Prog Neurobiol 1980, 14:69-97.
16. Cairns H, Olfield RC, Pennybacker JB, Whitteridge D Akinetic mutism with an epidermoid cyst of the 3rd ventricle. Brain 1941, 64:273-290.
17. Naville F Etudes sur les complications et les sequelles mentales de l'encephalite epidemique. Encephale 1922, 17:369-375.
18. Marin RS, Fogel BS, Hawkins J, Duffy J, Krupp B Apathy: a treatable syndrome. J Neuropsychiatry Clin Neurosci 1995, 7:23-30.
19. Liao C, Feng Z, Zhou D, et al. Dysfunction of fronto-limbic brain circuitry in depression. Neuroscience 2012, 201:231-238.
20. Jahanshahi M Willed action and its impairments. Cogn Neuropsychol 1998, 15:483-533.
21. Gross CG Three before their time: neuroscientists whose ideas were ignored by their contemporaries. Exp Brain Res 2009, 192:321-334.
22. Laplane D, Baulac M, Widlöcher D, Dubois B Pure psychic akinesia with bilateral lesions of basal ganglia. J Neurol Neurosurg Psychiatry 1984, 47:377-385.
23. Laplane D, Dubois B Auto-activation deficit: a basal ganglia related syndrome. Mov Disord 2001, 16:810-814.
24. Groenewegen HJ, Wright CI, Uylings HB The anatomical relationships of the prefrontal cortex with limbic structures and the basal ganglia. J Psychopharmacol 1997, 11:99-106.
25. Mega MS, Cummings JL, Salloway S, Malloy P The limbic system: an anatomic, phylogenetic, and clinical perspective. J Neuropsychiatry Clin Neurosci 1997, 9:315-330.
26. Drui G, Carnicella S, Carcenac C, et al. Loss of dopaminergic nigrostriatal neurons accounts for the motivational and affective deficits in Parkinson's disease. Mol Psychiatry 2014, 19:358-367.
27. Björklund A, Dunnett SB Dopamine neuron systems in the brain: an update. Trends Neurosci 2007, 30:194-202.
28. Goodwin GM Neuropsychological and neuroimaging evidence for the involvement of the frontal lobes in depression. J Psychopharmacol 1997, 11:115-122.
29. Mayberg HS, Liotti M, Brannan SK, et al. Reciprocal limbic-cortical function and negative mood: converging PET findings in depression and normal sadness. Am J Psychiatry 1999, 156:675-682.
30. Stone EA, Lin Y, Quartermain D A final common pathway for depression? Progress toward a general conceptual framework. Neurosci Biobehav Rev 2008, 32:508-524.
31. Buchsbaum MS, Wu J, Siegel BV, et al. Effect of sertraline on regional metabolic rate in patients with affective disorder. Biol Psychiatry 1997, 41:15-22.
32. Mayberg HS, Brannan SK, Tekell JL, et al. Regional metabolic effects of fluoxetine in major depression: serial changes and relationship to clinical response. Biol Psychiatry 2000, 48:830-843.
33. Eckert T, Tang C, Eidelberg D Assessment of the progression of Parkinson's disease: a metabolic network approach. Lancet Neurol 2007, 6:926-932.
34. Mega MS, Cohenour RC Akinetic mutism: disconnection of frontal-subcortical circuits. Neuropsychiatry Neuropsychol Behav Neurol 1997, 10:254-259.
35. Habib M Athymhormia and disorders of motivation in Basal Ganglia disease. J Neuropsychiatry Clin Neurosci 2004, 16:509-524.
36. Bush G, Luu P, Posner MI Cognitive and emotional influences in anterior cingulate cortex. Trends Cogn Sci 2000, 4:215-222.
37. Etkin A, Egner T, Kalisch R Emotional processing in anterior cingulate and medial prefrontal cortex. Trends Cogn Sci 2011, 15:85-93.
38. Ilango A, Kesner AJ, Keller KL, Stuber GD, Bonci A, Ikemoto S Similar roles of substantia nigra and ventral tegmental dopamine neurons in reward and aversion. J Neurosci 2014, 34:817-822.
39. Parent A, Hazrati LN Functional anatomy of the basal ganglia. I. The cortico-basal ganglia-thalamo-cortical loop. Brain Res Brain Res Rev 1995, 20:91-127.
40. Gray TS Functional and anatomical relationships among the amygdala, basal forebrain, ventral striatum, and cortex. An integrative discussion. Ann N Y Acad Sci 1999, 877:439-444.
41. Pont-Sunyer C, Hotter A, Gaig C, et al. The onset of nonmotor symptoms in Parkinson's disease (The ONSET PD Study). Mov Disord 2014, 30:229-237.
42. Aarsland D, Brønnick K, Alves G, et al. The spectrum of neuropsychiatric symptoms in patients with early untreated Parkinson's disease. J Neurol Neurosurg Psychiatry 2009, 80:928-930.
43. Barone P, Antonini A, Colosimo C, et al. The PRIAMO study: a multicenter assessment of nonmotor symptoms and their impact on quality of life in Parkinson's disease. Mov Disord 2009, 24:1641-1649.
44. Santangelo G, Barone P, Cuoco S, et al. Apathy in untreated, de novo patients with Parkinson's disease: validation study of Apathy Evaluation Scale. J Neurol 2014, 261:2319-2328.
45. Dujardin K, Sockeel P, Devos D, et al. Characteristics of apathy in Parkinson's disease. Mov Disord 2007, 22:778-784.
46. Kulisevsky J, Pagonabarraga J, Pascual-Sedano B, Garcia-Sanchez C, Gironell A Prevalence and correlates of neuropsychiatric symptoms in Parkinson's disease without dementia. Mov Disord 2008, 23:1889-1896.
47. Pluck GC, Brown RG Apathy in Parkinson's disease. J Neurol Neurosurg Psychiatry 2002, 73:636-642.
48. Aarsland D, Brønnick K, Ehrt U, et al. Neuropsychiatric symptoms in patients with Parkinson's disease and dementia: frequency, profile and associated care giver stress. J Neurol Neurosurg Psychiatry 2007, 78:36-42.
49. Kirsch-Darrow L, Fernandez HH, Marsiske M, Okun MS, Bowers D Dissociating apathy and depression in Parkinson disease. Neurology 2006, 67:33-38.
50. Dujardin K, Sockeel P, Delliaux M, Destee A, Defebvre L Apathy may herald cognitive decline and dementia in Parkinson's disease. Mov Disord 2009, 24:2391-2397.
51. Pedersen KF, Larsen JP, Alves G, Aarsland D Prevalence and clinical correlates of apathy in Parkinson's disease: a community-based study. Parkinsonism Relat Disord 2009, 15:295-299.
52. Laatu S, Karrasch M, Martikainen K, Marttila R Apathy is associated with activities of daily living ability in Parkinson's disease. Dement Geriatr Cogn Disord 2013, 35:249-255.
53. van Reekum R, Stuss DT, Ostrander L Apathy: why care?. J Neuropsychiatry Clin Neurosci 2005, 17:7-19.
54. Schiehser DM, Liu L, Lessig SL, et al. Predictors of discrepancies in Parkinson's disease patient and caregiver ratings of apathy, disinhibition, and executive dysfunction before and after diagnosis. J Int Neuropsychol Soc 2013, 19:295-304.
55. Zahodne LB, Gongvatana A, Cohen RA, Ott BR, Tremont G Are apathy and depression independently associated with longitudinal trajectories of cortical atrophy in mild cognitive impairment?. Am J Geriatr Psychiatry 2013, 21:1098-1106. the Alzheimer's Disease Neuroimaging Initiative.
56. Braak H, Del Tredici K, Rüb U, de Vos RA, Jansen Steur EN, Braak E Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 2003, 24:197-211.
57. Goetz CG, Emre M, Dubois B Parkinson's disease dementia: definitions, guidelines, and research perspectives in diagnosis. Ann Neurol 2008, 64(suppl 2):S81-S92.
58. Luk KC, Kehm V, Carroll J, et al. Pathological α-synuclein transmission initiates Parkinson-like neurodegeneration in nontransgenic mice. Science 2012, 338:949-953.
59. Isella V, Melzi P, Grimaldi M, et al. Clinical, neuropsychological, and morphometric correlates of apathy in Parkinson's disease. Mov Disord 2002, 17:366-371.
60. Starkstein SE, Mayberg HS, Preziosi TJ, Andrezejewski P, Leiguarda R, Robinson RG Reliability, validity, and clinical correlates of apathy in Parkinson's disease. J Neuropsychiatry Clin Neurosci 1992, 4:134-139.
61. Martinez-Corral M, Pagonabarraga J, Llebaria G, et al. Facial emotion recognition impairment in patients with Parkinson's disease and isolated apathy. Parkinsons Dis 2010, 2010:930627.
62. Robert G, Le Jeune F, Dondaine T, et al. Apathy and impaired emotional facial recognition networks overlap in Parkinson's disease: a PET study with conjunction analyses. J Neurol Neurosurg Psychiatry 2014, 85:1153-1158.
63. Kulisevsky J, Avila A, Barbanoj M, Antonijoan R, Berthier ML, Gironell A Acute effects of levodopa on neuropsychological performance in stable and fluctuating Parkinson's disease patients at different levodopa plasma levels. Brain 1996, 119:2121-2132.
64. Cools R, Barker RA, Sahakian BJ, Robbins TW L-Dopa medication remediates cognitive inflexibility, but increases impulsivity in patients with Parkinson's disease. Neuropsychologia 2003, 41:1431-1441.
65. Carlson JM, Foti D, Mujica-Parodi LR, Harmon-Jones E, Hajcak G Ventral striatal and medial prefrontal BOLD activation is correlated with reward-related electrocortical activity: a combined ERP and fMRI study. Neuroimage 2011, 57:1608-1616.
66. Martinez-Horta S, Riba J, de Bobadilla RF, et al. Apathy in Parkinson's disease: neurophysiological evidence of impaired incentive processing. J Neurosci 2014, 34:5918-5926.
67. Zahodne LB, Tremont G Unique effects of apathy and depression signs on cognition and function in amnestic mild cognitive impairment. Int J Geriatr Psychiatry 2013, 28:50-56.
68. Cubo E, Benito-León J, Coronell C, Armesto D Clinical correlates of apathy in patients recently diagnosed with Parkinson's disease: the ANIMO study. Neuroepidemiology 2012, 38:48-55. the ANIMO Study Group.
69. Leentjens AF, Dujardin K, Marsh L, et al. Apathy and anhedonia rating scales in Parkinson's disease: critique and recommendations. Mov Disord 2008, 23:2004-2014.
70. Leentjens AF, Dujardin K, Marsh L, et al. Anxiety rating scales in Parkinson's disease: critique and recommendations. Mov Disord 2008, 23:2015-2025.
71. Schrag A, Barone P, Brown RG, et al. Depression rating scales in Parkinson's disease: critique and recommendations. Mov Disord 2007, 22:1077-1092.
72. Eslinger PJ, Damasio AR Severe disturbance of higher cognition after bilateral frontal lobe ablation: patient EVR. Neurology 1985, 35:1731-1741.
73. Bhatia KP, Marsden CD The behavioural and motor consequences of focal lesions of the basal ganglia in man. Brain 1994, 117:859-876.
74. Engelborghs S, Marien P, Pickut BA, Verstraeten S, De Deyn PP Loss of psychic self-activation after paramedian bithalamic infarction. Stroke 2000, 31:1762-1765.
75. Aarsland D, Larsen JP, Lim NG, et al. Range of neuropsychiatric disturbances in patients with Parkinson's disease. J Neurol Neurosurg Psychiatry 1999, 67:492-496.
76. Quaranta D, Marra C, Rossi C, Gainotti G, Masullo C Different apathy profile in behavioral variant of frontotemporal dementia and Alzheimer's disease: a preliminary investigation. Curr Gerontol Geriatr Res 2012, 2012:719250.
77. Craufurd D, Thompson JC, Snowden JS Behavioral changes in Huntington Disease. Neuropsychiatry Neuropsychol Behav Neurol 2001, 14:219-226.
78. Aarsland D, Cummings JL, Larsen JP Neuropsychiatric differences between Parkinson's disease with dementia and Alzheimer's disease. Int J Geriatr Psychiatry 2001, 16:184-191.
79. Benoit M, Koulibaly PM, Migneco O, Darcourt J, Pringuey DJ, Robert PH Brain perfusion in Alzheimer's disease with and without apathy: a SPECT study with statistical parametric mapping analysis. Psychiatry Res 2002, 114:103-111.
80. LanctÔt KL, Moosa S, Herrmann N, et al. A SPECT study of apathy in Alzheimer's disease. Dement Geriatr Cogn Disord 2007, 24:65-72.
81. Marshall GA, Monserratt L, Harwood D, Mandelkern M, Cummings JL, Sultzer DL Positron emission tomography metabolic correlates of apathy in Alzheimer disease. Arch Neurol 2007, 64:1015-1020.
82. Migneco O, Benoit M, Koulibaly PM, et al. Perfusion brain SPECT and statistical parametric mapping analysis indicate that apathy is a cingulate syndrome: a study in Alzheimer's disease and nondemented patients. Neuroimage 2001, 13:896-902.
83. Thobois S, Ardouin C, Lhommée E, et al. Non-motor dopamine withdrawal syndrome after surgery for Parkinson's disease: predictors and underlying mesolimbic denervation. Brain 2010, 133:1111-1127.
84. Remy P, Doder M, Lees A, Turjanski N, Brooks D Depression in Parkinson's disease: loss of dopamine and noradrenaline innervation in the limbic system. Brain 2005, 128:1314-1322.
85. Robert GH, Le Jeune F, Lozachmeur C, et al. Preoperative factors of apathy in subthalamic stimulated Parkinson disease: a PET study. Neurology 2014, 83:1620-1626.
86. Bechara A, Damasio H, Damasio AR Emotion, decision making and the orbitofrontal cortex. Cereb Cortex 2000, 10:295-307.
87. Chaudhuri KR, Martinez-Martin P, Antonini A, et al. Rotigotine and specific non-motor symptoms of Parkinson's disease: post hoc analysis of RECOVER. Parkinsonism Relat Disord 2013, 19:660-665.
88. Steeves TD, Miyasaki J, Zurowski M, et al. Increased striatal dopamine release in Parkinsonian patients with pathological gambling: a [11C] raclopride PET study. Brain 2009, 132:1376-1385.
89. van Eimeren T, Pellecchia G, Cilia R, et al. Drug-induced deactivation of inhibitory networks predicts pathological gambling in PD. Neurology 2010, 75:1711-1716.
90. Pondal M, Marras C, Miyasaki J, et al. Clinical features of dopamine agonist withdrawal syndrome in a movement disorders clinic. J Neurol Neurosurg Psychiatry 2013, 84:130-135.
91. Lhommée E, Klinger H, Thobois S, et al. Subthalamic stimulation in Parkinson's disease: restoring the balance of motivated behaviours. Brain 2012, 135:1463-1477.
92. Castrioto A, Lhommée E, Moro E, Krack P Mood and behavioural effects of subthalamic stimulation in Parkinson's disease. Lancet Neurol 2014, 13:287-305.
93. Rabinak CA, Nirenberg MJ Dopamine agonist withdrawal syndrome in Parkinson disease. Arch Neurol 2010, 67:58-63.
94. Monchi O, Petrides M, Doyon J, Postuma RB, Worsley K, Dagher A Neural bases of set-shifting deficits in Parkinson's disease. J Neurosci 2004, 24:702-710.
95. Monchi O, Petrides M, Mejia-Constain B, Strafella AP Cortical activity in Parkinson's disease during executive processing depends on striatal involvement. Brain 2007, 130:233-244.
96. Huang C, Ravdin LD, Nirenberg MJ, et al. Neuroimaging markers of motor and nonmotor features of Parkinson's disease: an 18f fluorodeoxyglucose positron emission computed tomography study. Dement Geriatr Cogn Disord 2013, 35:183-196.
97. Le Jeune F, Drapier D, Bourguignon A, et al. Subthalamic nucleus stimulation in Parkinson disease induces apathy: a PET study. Neurology 2009, 73:1746-1751.
98. Robert PH, Clairet S, Benoit M, et al. The apathy inventory: assessment of apathy and awareness in Alzheimer's disease, Parkinson's disease and mild cognitive impairment. Int J Geriatr Psychiatry 2002, 17:1099-1105.
99. Krack P, Pollak P, Limousin P, et al. Subthalamic nucleus or internal pallidal stimulation in young onset Parkinson's disease. Brain 1998, 121:451-457.
100. Drapier D, Drapier S, Sauleau P, et al. Does subthalamic nucleus stimulation induce apathy in Parkinson's disease?. J Neurol 2006, 253:1083-1091.
101. Krack P, Batir A, Van Blercom N, et al. Five-year follow-up of bilateral stimulation of the subthalamic nucleus in advanced Parkinson's disease. N Engl J Med 2003, 349:1925-1934.
102. Castrioto A, Volkmann J, Krack P Postoperative management of deep brain stimulation in Parkinson's disease. Handb Clin Neurol 2013, 116:129-146.
103. Schuepbach WM, Rau J, Knudsen K, et al. Neurostimulation for Parkinson's disease with early motor complications. N Engl J Med 2013, 368:610-622. the EARLYSTIM Study Group.
104. Czernecki V, Pillon B, Houeto JL, et al. Does bilateral stimulation of the subthalamic nucleus aggravate apathy in Parkinson's disease?. J Neurol Neurosurg Psychiatry 2005, 76:775-779.
105. Funkiewiez A, Ardouin C, Krack P, et al. Acute psychotropic effects of bilateral subthalamic nucleus stimulation and levodopa in Parkinson's disease. Mov Disord 2003, 18:524-530.
106. Schneider F, Habel U, Volkmann J, et al. Deep brain stimulation of the subthalamic nucleus enhances emotional processing in Parkinson disease. Arch Gen Psychiatry 2003, 60:296-302.
107. Castrioto A, Kistner A, Klinger H, et al. Psychostimulant effect of levodopa: reversing sensitisation is possible. J Neurol Neurosurg Psychiatry 2013, 84:18-22.
108. Czernecki V, Schupbach M, Yaici S, et al. Apathy following subthalamic stimulation in Parkinson disease: a dopamine responsive symptom. Mov Disord 2008, 23:964-969.
109. Thobois S, Lhommée E, Klinger H, et al. Parkinsonian apathy responds to dopaminergic stimulation of D2/D3 receptors with piribedil. Brain 2013, 136:1568-1577.
110. de la Fuente-Fernández R, Pal PK, Vingerhoets FJ, et al. Evidence for impaired presynaptic dopamine function in parkinsonian patients with motor fluctuations. J Neural Transm 2000, 107:49-57.
111. Braak H, Rüb U, Del Tredici K Cognitive decline correlates with neuropathological stage in Parkinson's disease. J Neurol Sci 2006, 248:255-258.
112. Braak H, Rüb U, Jansen Steur EN, Del Tredici K, de Vos RA Cognitive status correlates with neuropathologic stage in Parkinson disease. Neurology 2005, 64:1404-1410.
113. Hely MA, Morris JG, Reid WG, Trafficante R Sydney Multicenter Study of Parkinson's disease: non-L-dopa-responsive problems dominate at 15 years. Mov Disord 2005, 20:190-199.
114. Hely MA, Reid WG, Adena MA, Halliday GM, Morris JG The Sydney multicenter study of Parkinson's disease: the inevitability of dementia at 20 years. Mov Disord 2008, 23:837-844.
115. Ardouin C, Pillon B, Peiffer E, et al. Bilateral subthalamic or pallidal stimulation for Parkinson's disease affects neither memory nor executive functions: a consecutive series of 62 patients. Ann Neurol 1999, 46:217-223.
116. Parsons TD, Rogers SA, Braaten AJ, Woods SP, Tröster AI Cognitive sequelae of subthalamic nucleus deep brain stimulation in Parkinson's disease: a meta-analysis. Lancet Neurol 2006, 5:578-588.
117. Witt K, Granert O, Daniels C, et al. Relation of lead trajectory and electrode position to neuropsychological outcomes of subthalamic neurostimulation in Parkinson's disease: results from a randomized trial. Brain 2013, 136:2109-2119.
118. Rodriguez-Oroz MC, Moro E, Krack P Long-term outcomes of surgical therapies for Parkinson's disease. Mov Disord 2012, 27:1718-1728.
119. Ye Z, Hammer A, Camara E, Münte TF Pramipexole modulates the neural network of reward anticipation. Hum Brain Mapp 2011, 32:800-811.
120. Kulisevsky J, Pagonabarraga J, Martinez-Corral M Changes in artistic style and behaviour in Parkinson's disease: dopamine and creativity. J Neurol 2009, 256:816-819.
121. Lhommée E, Batir A, Quesada JL, et al. Dopamine and the biology of creativity: lessons from Parkinson's disease. Front Neurol 2014, 5:55.
122. Ray NJ, Miyasaki JM, Zurowski M, et al. Extrastriatal dopaminergic abnormalities of DA homeostasis in Parkinson's patients with medication-induced pathological gambling: a [11C] FLB-457 and PET study. Neurobiol Dis 2012, 48:519-525.
123. Sockeel P, Dujardin K, Devos D, Denève C, Destée A, Defebvre L The Lille apathy rating scale (LARS), a new instrument for detecting and quantifying apathy: validation in Parkinson's disease. J Neurol Neurosurg Psychiatry 2006, 77:579-584.
124. Cummings JL, Mega M, Gray K, Rosenberg-Thompson S, Carusi DA, Gornbein J The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology 1994, 44:2308-2314.
125. Zahodne LB, Okun MS, Foote KD, et al. Cognitive declines one year after unilateral deep brain stimulation surgery in Parkinson's disease: a controlled study using reliable change. Clin Neuropsychol 2009, 23:385-405.
126. Starkstein SE, Merello M, Jorge R, Brockman S, Bruce D, Power B The syndromal validity and nosological position of apathy in Parkinson's disease. Mov Disord 2009, 24:1211-1216.
127. Drijgers RL, Dujardin K, Reijnders JS, Defebvre L, Leentjens AF Validation of diagnostic criteria for apathy in Parkinson's disease. Parkinsonism Relat Disord 2010, 16:656-660.
128. Robert P, Onyike CU, Leentjens AF, et al. Proposed diagnostic criteria for apathy in Alzheimer's disease and other neuropsychiatric disorders. Eur Psychiatry 2009, 24:98-104.
129. Martinez-Martin P, Rodriguez-Blazquez C, Kurtis MM, Chaudhuri KR The impact of non-motor symptoms on health-related quality of life of patients with Parkinson's disease. Mov Disord 2011, 26:399-406.
130. Devos D, Moreau C, Maltête D, et al. Rivastigmine in apathetic but dementia and depression-free patients with Parkinson's disease: a double-blind, placebo-controlled, randomised clinical trial. J Neurol Neurosurg Psychiatry 2014, 85:668-674.
131. Leentjens AF, Koester J, Fruh B, Shephard DT, Barone P, Houben JJ The effect of pramipexole on mood and motivational symptoms in Parkinson's disease: a meta-analysis of placebo-controlled studies. Clin Ther 2009, 31:89-98.
132. Chatterjee A, Fahn S Methylphenidate treats apathy in Parkinson's disease. J Neuropsychiatry Clin Neurosci 2002, 14:461-462.
133. Moreau C, Delval A, Defebvre L, et al. Methylphenidate for gait hypokinesia and freezing in patients with Parkinson's disease undergoing subthalamic stimulation: a multicentre, parallel, randomised, placebo-controlled trial. Lancet Neurol 2012, 11:589-596. the Parkgait-II study group.
134. Herrmann N, Rothenburg LS, Black SE, et al. Methylphenidate for the treatment of apathy in Alzheimer disease: prediction of response using dextroamphetamine challenge. J Clin Psychopharmacol 2008, 28:296-301.
135. LanctÔt KL, Chau SA, Herrmann N, et al. Effect of methylphenidate on attention in apathetic AD patients in a randomized, placebo-controlled trial. Int Psychogeriatr 2014, 26:239-246.
136. Rosenberg PB, LanctÔt KL, Drye LT, et al. Safety and efficacy of methylphenidate for apathy in Alzheimer's disease: a randomized, placebo-controlled trial. J Clin Psychiatry 2013, 74:810-816. the ADMET Investigators.
137. Halliday AM, Nathan PW Methyl phenidate in parkinsonism. BMJ 1961, 1:1652-1655.
138. Cantello R, Aguggia M, Gilli M, et al. Major depression in Parkinson's disease and the mood response to intravenous methylphenidate: possible role of the "hedonic" dopamine synapse. J Neurol Neurosurg Psychiatry 1989, 52:724-731.
139. Houeto JL, Mesnage V, Mallet L, et al. Behavioural disorders, Parkinson's disease and subthalamic stimulation. J Neurol Neurosurg Psychiatry 2002, 72:701-707.
140. Zahodne LB, Bernal-Pacheco O, Bowers D, et al. Are selective serotonin reuptake inhibitors associated with greater apathy in Parkinson's disease?. J Neuropsychiatry Clin Neurosci 2012, 24:326-330.
141. Wongpakaran N, van Reekum R, Wongpakaran T, Clarke D Selective serotonin reuptake inhibitor use associates with apathy among depressed elderly: a case-control study. Ann Gen Psychiatry 2007, 6:7.
142. Corcoran C, Wong ML, O'Keane V Bupropion in the management of apathy. J Psychopharmacol 2004, 18:133-135.
143. Lyketsos CG, Steinberg M, Tschanz JT, Norton MC, Steffens DC, Breitner JC Mental and behavioral disturbances in dementia: findings from the Cache County Study on Memory in Aging. Am J Psychiatry 2000, 157:708-714.
144. Starkstein SE, Jorge R, Mizrahi R, Robinson RG A prospective longitudinal study of apathy in Alzheimer's disease. J Neurol Neurosurg Psychiatry 2006, 77:8-11.
145. Kulisevsky J, Litvan I, Berthier ML, Pascual-Sedano B, Paulsen JS, Cummings JL Neuropsychiatric assessment of Gilles de la Tourette patients: comparative study with other hyperkinetic and hypokinetic movement disorders. Mov Disord 2001, 16:1098-1104.
146. Levy ML, Cummings JL, Fairbanks LA, et al. Apathy is not depression. J Neuropsychiatry Clin Neurosci 1998, 10:314-319.
147. Paulsen JS, Ready RE, Hamilton JM, Mega MS, Cummings JL Neuropsychiatric aspects of Huntington's disease. J Neurol Neurosurg Psychiatry 2001, 71:310-314.
148. Thompson JC, Harris J, Sollom AC, et al. Longitudinal evaluation of neuropsychiatric symptoms in Huntington's disease. J Neuropsychiatry Clin Neurosci 2012, 24:53-60.
149. Pasquier F, Lebert F, Lavenu I, Guillaume B The clinical picture of frontotemporal dementia: diagnosis and follow-up. Dement Geriatr Cogn Disord 1999, 10(suppl 1):10-14.
150. Tabrizi SJ, Scahill RI, Owen G, et al. Predictors of phenotypic progression and disease onset in premanifest and early-stage Huntington's disease in the TRACK-HD study: analysis of 36-month observational data. Lancet Neurol 2013, 12:637-649. the TRACK-HD Investigators.
151. Bathgate D, Snowden JS, Varma A, Blackshaw A, Neary D Behaviour in frontotemporal dementia, Alzheimer's disease and vascular dementia. Acta Neurol Scand 2001, 103:367-378.
152. Litvan I, Mega MS, Cummings JL, Fairbanks L Neuropsychiatric aspects of progressive supranuclear palsy. Neurology 1996, 47:1184-1189.
153. Naarding P, Janzing JG, Eling P, van der Werf S, Kremer B Apathy is not depression in Huntington's disease. J Neuropsychiatry Clin Neurosci 2009, 21:266-270.
154. Eusebio A, Witjas T, Cohen J, et al. Subthalamic nucleus stimulation and compulsive use of dopaminergic medication in Parkinson's disease. J Neurol Neurosurg Psychiatry 2013, 84:868-874.
155. Pedersen KF, Alves G, Brønnick K, Aarsland D, Tysnes OB, Larsen JP Apathy in drug-naïve patients with incident Parkinson's disease: the Norwegian ParkWest study. J Neurol 2010, 257:217-223.
156. Boyle PA, Malloy PF Treating apathy in Alzheimer's disease. Dement Geriatr Cogn Disord 2004, 17:91-99.
157. Drijgers RL, Aalten P, Winogrodzka A, Verhey FR, Leentjens AF Pharmacological treatment of apathy in neurodegenerative diseases: a systematic review. Dement Geriatr Cogn Disord 2009, 28:13-22.